

# **Atorvastatin Calcium Market By Form (Tablets, Others) , By Application (Hypercholesterolemia, Hyperlipidemia, Others) By Distribution channel (Hospital pharmacies, Drug store & retail pharmacies, Online providers.) : Global Opportunity Analysis and Industry Forecast, 2024-2033**

<https://marketpublishers.com/r/ACB76400BC89EN.html>

Date: July 2024

Pages: 280

Price: US\$ 2,655.00 (Single User License)

ID: ACB76400BC89EN

## **Abstracts**

The atorvastatin calcium market was valued at \$298.3 million in 2023, and is projected to reach \$487.8 million by 2033, growing at a CAGR of 5% from 2024 to 2033.

Atorvastatin calcium is a statin medication, which acts as the first line of treatment for the prevention of cardiovascular diseases. It lowers the cholesterol levels in the blood by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver. This medication is effective in lowering low-density lipoprotein (LDL) cholesterol, and can also help to raise high-density lipoprotein (HDL) cholesterol. By managing cholesterol levels, atorvastatin calcium plays a crucial role in preventing heart attacks, strokes, and other serious cardiovascular events.

The growth of the global atorvastatin calcium market is majorly driven by alarming increase in prevalence of cardiovascular diseases. According to the World Heart Federation, cardiovascular diseases are the leading cause of death worldwide as compared to any other cause. Approximately 20.5 million deaths were reported in 2021 across the globe. In addition, surge in geriatric population significantly contributes toward the market growth. This is attributed to the fact that aged individuals are highly susceptible to hypercholesterolemia and related cardiovascular conditions, which, in turn, leads to higher demand for cholesterol-lowering medications like atorvastatin, thereby boosting the market growth. As per AHA 2019 Heart Disease and

Stroke Statistical Update, the incidence of cardiovascular diseases was reported to be 77.2% in males and 78.2% in females, from ages 60–79 years. Moreover, rise in sedentary lifestyles and unhealthy eating patterns are leading to higher cholesterol levels among the population, thereby increasing the need for atorvastatin calcium. Furthermore, rise in public awareness of the importance of managing cholesterol levels for overall health and availability of generic versions of atorvastatin calcium boost the growth of the global market. Increase in popularity of combination therapies acts a key trend that is expected to augment the market growth. For instance, the use of atorvastatin calcium in combination with other drugs, such as ezetimibe, is becoming more common to enhance therapeutic outcomes for managing cholesterol levels. However, rise in concerns about potential side effects of atorvastatin calcium such as muscle pain, liver damage, and interactions with other medications can limit its use, which hampers the market growth. In addition, availability of alternative statins and other cholesterol-lowering drugs acts as key deterrent factor of the global market. On the contrary, innovations in drug formulation and delivery systems are enhancing the efficacy and convenience of atorvastatin calcium, which are expected to offer lucrative opportunities for the market growth during the forecast period.

The global atorvastatin calcium market is segmented into form, application, distribution channel, and region. On the basis of form, the market is categorized into tablets and others. By application, it is divided into hypercholesterolemia, hyperlipidemia, and others. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

## Key Findings

On the basis of form, the tablets segment dominated the market in 2023, and is expected to dominate from 2024 to 2033.

By application, hypercholesterolemia is anticipated to be the lucrative segment in the global atorvastatin calcium market in the coming years.

Depending on distribution channel, online pharmacies is projected to emerge as the leading segment by 2033.

Region wise, North America held the largest market share in terms of revenue in 2023, and is expected to dominate the atorvastatin calcium market during the forecast

period.

## Competition Analysis

Competitive analysis and profiles of the major players in the global atorvastatin calcium market include Mylan Pharmaceuticals Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd, Merck and Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc., and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

Quarterly Update and\* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support\* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization\* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response\*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Patient/epidemiology data at country, region, global level

Additional company profiles with specific client's interest

Expanded list for Company Profiles

Historic market data

SWOT Analysis

## Key Market Segments

### By Form

Tablets

Others

### By Application

Hypercholesterolemia

Hyperlipidemia

Others

### By Distribution Channel

Hospital pharmacies

Drug store retail pharmacies

Online providers.

## By Region

North America

U.S.

Canada

Mexico

Europe

France

Germany

Italy

Spain

UK

Rest of Europe

Asia-Pacific

China

Japan

India

South Korea

Australia

Rest of Asia-Pacific

LAMEA

Brazil

South Africa

Saudi Arabia

Rest of LAMEA

Key Market Players

Mylan Pharmaceuticals Inc.

Novartis AG

GlaxoSmithKline plc

Amgen Inc.

Sanofi SA

Teva Pharmaceuticals Industries Ltd

Merck and Co. Inc.

Bristol-Myers Squibb Company

AstraZeneca Plc

Pfizer Inc.

## Contents

### CHAPTER 1: INTRODUCTION

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models

### CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO Perspective

### CHAPTER 3: MARKET LANDSCAPE

- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Investment Pockets
  - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
  - 3.4.1. Drivers
  - 3.4.2. Restraints
  - 3.4.3. Opportunities

### CHAPTER 4: AUTOIMMUNE DISEASE TESTING MARKET, BY PRODUCT TYPE

- 4.1. Market Overview
  - 4.1.1 Market Size and Forecast, By Product Type
- 4.2. Instruments
  - 4.2.1. Key Market Trends, Growth Factors and Opportunities

- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Consumables And Kits
  - 4.3.1. Key Market Trends, Growth Factors and Opportunities
  - 4.3.2. Market Size and Forecast, By Region
  - 4.3.3. Market Share Analysis, By Country

## **CHAPTER 5: AUTOIMMUNE DISEASE TESTING MARKET, BY DISEASE TYPE**

- 5.1. Market Overview
  - 5.1.1 Market Size and Forecast, By Disease Type
- 5.2. Rheumatoid Arthritis
  - 5.2.1. Key Market Trends, Growth Factors and Opportunities
  - 5.2.2. Market Size and Forecast, By Region
  - 5.2.3. Market Share Analysis, By Country
- 5.3. Systemic Lupus Erythematosus
  - 5.3.1. Key Market Trends, Growth Factors and Opportunities
  - 5.3.2. Market Size and Forecast, By Region
  - 5.3.3. Market Share Analysis, By Country
- 5.4. Scleroderma
  - 5.4.1. Key Market Trends, Growth Factors and Opportunities
  - 5.4.2. Market Size and Forecast, By Region
  - 5.4.3. Market Share Analysis, By Country
- 5.5. Vasculitis
  - 5.5.1. Key Market Trends, Growth Factors and Opportunities
  - 5.5.2. Market Size and Forecast, By Region
  - 5.5.3. Market Share Analysis, By Country
- 5.6. Inflammatory Bowel Disease
  - 5.6.1. Key Market Trends, Growth Factors and Opportunities
  - 5.6.2. Market Size and Forecast, By Region
  - 5.6.3. Market Share Analysis, By Country
- 5.7. Others
  - 5.7.1. Key Market Trends, Growth Factors and Opportunities
  - 5.7.2. Market Size and Forecast, By Region
  - 5.7.3. Market Share Analysis, By Country

## **CHAPTER 6: AUTOIMMUNE DISEASE TESTING MARKET, BY TEST TYPE**

- 6.1. Market Overview



- 6.1.1 Market Size and Forecast, By Test Type
- 6.2. Antibodies And Immunologic Test
  - 6.2.1. Key Market Trends, Growth Factors and Opportunities
  - 6.2.2. Market Size and Forecast, By Region
  - 6.2.3. Market Share Analysis, By Country
- 6.3. Inflammatory Markers
  - 6.3.1. Key Market Trends, Growth Factors and Opportunities
  - 6.3.2. Market Size and Forecast, By Region
  - 6.3.3. Market Share Analysis, By Country
- 6.4. Routine Laboratory Tests
  - 6.4.1. Key Market Trends, Growth Factors and Opportunities
  - 6.4.2. Market Size and Forecast, By Region
  - 6.4.3. Market Share Analysis, By Country
- 6.5. Anti-Thyroglobulin Antibody
  - 6.5.1. Key Market Trends, Growth Factors and Opportunities
  - 6.5.2. Market Size and Forecast, By Region
  - 6.5.3. Market Share Analysis, By Country
- 6.6. Others
  - 6.6.1. Key Market Trends, Growth Factors and Opportunities
  - 6.6.2. Market Size and Forecast, By Region
  - 6.6.3. Market Share Analysis, By Country

## **CHAPTER 7: AUTOIMMUNE DISEASE TESTING MARKET, BY END USER**

- 7.1. Market Overview
  - 7.1.1 Market Size and Forecast, By End User
- 7.2. Hospitals And Clinics
  - 7.2.1. Key Market Trends, Growth Factors and Opportunities
  - 7.2.2. Market Size and Forecast, By Region
  - 7.2.3. Market Share Analysis, By Country
- 7.3. Clinical Laboratories
  - 7.3.1. Key Market Trends, Growth Factors and Opportunities
  - 7.3.2. Market Size and Forecast, By Region
  - 7.3.3. Market Share Analysis, By Country
- 7.4. Others
  - 7.4.1. Key Market Trends, Growth Factors and Opportunities
  - 7.4.2. Market Size and Forecast, By Region
  - 7.4.3. Market Share Analysis, By Country

## CHAPTER 8: AUTOIMMUNE DISEASE TESTING MARKET, BY REGION

### 8.1. Market Overview

#### 8.1.1 Market Size and Forecast, By Region

### 8.2. North America

#### 8.2.1. Key Market Trends and Opportunities

#### 8.2.2. Market Size and Forecast, By Product Type

#### 8.2.3. Market Size and Forecast, By Disease Type

#### 8.2.4. Market Size and Forecast, By Test Type

#### 8.2.5. Market Size and Forecast, By End User

#### 8.2.6. Market Size and Forecast, By Country

#### 8.2.7. U.S. Autoimmune Disease Testing Market

##### 8.2.7.1. Market Size and Forecast, By Product Type

##### 8.2.7.2. Market Size and Forecast, By Disease Type

##### 8.2.7.3. Market Size and Forecast, By Test Type

##### 8.2.7.4. Market Size and Forecast, By End User

#### 8.2.8. Canada Autoimmune Disease Testing Market

##### 8.2.8.1. Market Size and Forecast, By Product Type

##### 8.2.8.2. Market Size and Forecast, By Disease Type

##### 8.2.8.3. Market Size and Forecast, By Test Type

##### 8.2.8.4. Market Size and Forecast, By End User

#### 8.2.9. Mexico Autoimmune Disease Testing Market

##### 8.2.9.1. Market Size and Forecast, By Product Type

##### 8.2.9.2. Market Size and Forecast, By Disease Type

##### 8.2.9.3. Market Size and Forecast, By Test Type

##### 8.2.9.4. Market Size and Forecast, By End User

### 8.3. Europe

#### 8.3.1. Key Market Trends and Opportunities

#### 8.3.2. Market Size and Forecast, By Product Type

#### 8.3.3. Market Size and Forecast, By Disease Type

#### 8.3.4. Market Size and Forecast, By Test Type

#### 8.3.5. Market Size and Forecast, By End User

#### 8.3.6. Market Size and Forecast, By Country

#### 8.3.7. Germany Autoimmune Disease Testing Market

##### 8.3.7.1. Market Size and Forecast, By Product Type

##### 8.3.7.2. Market Size and Forecast, By Disease Type

##### 8.3.7.3. Market Size and Forecast, By Test Type

##### 8.3.7.4. Market Size and Forecast, By End User

#### 8.3.8. France Autoimmune Disease Testing Market

- 8.3.8.1. Market Size and Forecast, By Product Type
- 8.3.8.2. Market Size and Forecast, By Disease Type
- 8.3.8.3. Market Size and Forecast, By Test Type
- 8.3.8.4. Market Size and Forecast, By End User
- 8.3.9. UK Autoimmune Disease Testing Market
  - 8.3.9.1. Market Size and Forecast, By Product Type
  - 8.3.9.2. Market Size and Forecast, By Disease Type
  - 8.3.9.3. Market Size and Forecast, By Test Type
  - 8.3.9.4. Market Size and Forecast, By End User
- 8.3.10. Italy Autoimmune Disease Testing Market
  - 8.3.10.1. Market Size and Forecast, By Product Type
  - 8.3.10.2. Market Size and Forecast, By Disease Type
  - 8.3.10.3. Market Size and Forecast, By Test Type
  - 8.3.10.4. Market Size and Forecast, By End User
- 8.3.11. Spain Autoimmune Disease Testing Market
  - 8.3.11.1. Market Size and Forecast, By Product Type
  - 8.3.11.2. Market Size and Forecast, By Disease Type
  - 8.3.11.3. Market Size and Forecast, By Test Type
  - 8.3.11.4. Market Size and Forecast, By End User
- 8.3.12. Rest of Europe Autoimmune Disease Testing Market
  - 8.3.12.1. Market Size and Forecast, By Product Type
  - 8.3.12.2. Market Size and Forecast, By Disease Type
  - 8.3.12.3. Market Size and Forecast, By Test Type
  - 8.3.12.4. Market Size and Forecast, By End User
- 8.4. Asia-Pacific
  - 8.4.1. Key Market Trends and Opportunities
  - 8.4.2. Market Size and Forecast, By Product Type
  - 8.4.3. Market Size and Forecast, By Disease Type
  - 8.4.4. Market Size and Forecast, By Test Type
  - 8.4.5. Market Size and Forecast, By End User
  - 8.4.6. Market Size and Forecast, By Country
  - 8.4.7. Japan Autoimmune Disease Testing Market
    - 8.4.7.1. Market Size and Forecast, By Product Type
    - 8.4.7.2. Market Size and Forecast, By Disease Type
    - 8.4.7.3. Market Size and Forecast, By Test Type
    - 8.4.7.4. Market Size and Forecast, By End User
  - 8.4.8. China Autoimmune Disease Testing Market
    - 8.4.8.1. Market Size and Forecast, By Product Type
    - 8.4.8.2. Market Size and Forecast, By Disease Type

- 8.4.8.3. Market Size and Forecast, By Test Type
- 8.4.8.4. Market Size and Forecast, By End User
- 8.4.9. India Autoimmune Disease Testing Market
  - 8.4.9.1. Market Size and Forecast, By Product Type
  - 8.4.9.2. Market Size and Forecast, By Disease Type
  - 8.4.9.3. Market Size and Forecast, By Test Type
  - 8.4.9.4. Market Size and Forecast, By End User
- 8.4.10. Australia Autoimmune Disease Testing Market
  - 8.4.10.1. Market Size and Forecast, By Product Type
  - 8.4.10.2. Market Size and Forecast, By Disease Type
  - 8.4.10.3. Market Size and Forecast, By Test Type
  - 8.4.10.4. Market Size and Forecast, By End User
- 8.4.11. South Korea Autoimmune Disease Testing Market
  - 8.4.11.1. Market Size and Forecast, By Product Type
  - 8.4.11.2. Market Size and Forecast, By Disease Type
  - 8.4.11.3. Market Size and Forecast, By Test Type
  - 8.4.11.4. Market Size and Forecast, By End User
- 8.4.12. Rest of Asia-Pacific Autoimmune Disease Testing Market
  - 8.4.12.1. Market Size and Forecast, By Product Type
  - 8.4.12.2. Market Size and Forecast, By Disease Type
  - 8.4.12.3. Market Size and Forecast, By Test Type
  - 8.4.12.4. Market Size and Forecast, By End User
- 8.5. LAMEA
  - 8.5.1. Key Market Trends and Opportunities
  - 8.5.2. Market Size and Forecast, By Product Type
  - 8.5.3. Market Size and Forecast, By Disease Type
  - 8.5.4. Market Size and Forecast, By Test Type
  - 8.5.5. Market Size and Forecast, By End User
  - 8.5.6. Market Size and Forecast, By Country
  - 8.5.7. Brazil Autoimmune Disease Testing Market
    - 8.5.7.1. Market Size and Forecast, By Product Type
    - 8.5.7.2. Market Size and Forecast, By Disease Type
    - 8.5.7.3. Market Size and Forecast, By Test Type
    - 8.5.7.4. Market Size and Forecast, By End User
  - 8.5.8. Saudi Arabia Autoimmune Disease Testing Market
    - 8.5.8.1. Market Size and Forecast, By Product Type
    - 8.5.8.2. Market Size and Forecast, By Disease Type
    - 8.5.8.3. Market Size and Forecast, By Test Type
    - 8.5.8.4. Market Size and Forecast, By End User

- 8.5.9. South Africa Autoimmune Disease Testing Market
  - 8.5.9.1. Market Size and Forecast, By Product Type
  - 8.5.9.2. Market Size and Forecast, By Disease Type
  - 8.5.9.3. Market Size and Forecast, By Test Type
  - 8.5.9.4. Market Size and Forecast, By End User
- 8.5.10. Rest of LAMEA Autoimmune Disease Testing Market
  - 8.5.10.1. Market Size and Forecast, By Product Type
  - 8.5.10.2. Market Size and Forecast, By Disease Type
  - 8.5.10.3. Market Size and Forecast, By Test Type
  - 8.5.10.4. Market Size and Forecast, By End User

## **CHAPTER 9: COMPETITIVE LANDSCAPE**

- 9.1. Introduction
- 9.2. Top Winning Strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Top Player Positioning, 2023

## **CHAPTER 10: COMPANY PROFILES**

- 10.1. F. Hoffmann-La Roche Ltd
  - 10.1.1. Company Overview
  - 10.1.2. Key Executives
  - 10.1.3. Company Snapshot
  - 10.1.4. Operating Business Segments
  - 10.1.5. Product Portfolio
  - 10.1.6. Business Performance
  - 10.1.7. Key Strategic Moves and Developments
- 10.2. Siemens
  - 10.2.1. Company Overview
  - 10.2.2. Key Executives
  - 10.2.3. Company Snapshot
  - 10.2.4. Operating Business Segments
  - 10.2.5. Product Portfolio
  - 10.2.6. Business Performance
  - 10.2.7. Key Strategic Moves and Developments
- 10.3. Thermo Fisher Scientific Inc.

- 10.3.1. Company Overview
- 10.3.2. Key Executives
- 10.3.3. Company Snapshot
- 10.3.4. Operating Business Segments
- 10.3.5. Product Portfolio
- 10.3.6. Business Performance
- 10.3.7. Key Strategic Moves and Developments
- 10.4. Quest Diagnostics
  - 10.4.1. Company Overview
  - 10.4.2. Key Executives
  - 10.4.3. Company Snapshot
  - 10.4.4. Operating Business Segments
  - 10.4.5. Product Portfolio
  - 10.4.6. Business Performance
  - 10.4.7. Key Strategic Moves and Developments
- 10.5. Abbott
  - 10.5.1. Company Overview
  - 10.5.2. Key Executives
  - 10.5.3. Company Snapshot
  - 10.5.4. Operating Business Segments
  - 10.5.5. Product Portfolio
  - 10.5.6. Business Performance
  - 10.5.7. Key Strategic Moves and Developments
- 10.6. Werfen, S.A.
  - 10.6.1. Company Overview
  - 10.6.2. Key Executives
  - 10.6.3. Company Snapshot
  - 10.6.4. Operating Business Segments
  - 10.6.5. Product Portfolio
  - 10.6.6. Business Performance
  - 10.6.7. Key Strategic Moves and Developments
- 10.7. Trinity Biotech
  - 10.7.1. Company Overview
  - 10.7.2. Key Executives
  - 10.7.3. Company Snapshot
  - 10.7.4. Operating Business Segments
  - 10.7.5. Product Portfolio
  - 10.7.6. Business Performance
  - 10.7.7. Key Strategic Moves and Developments

## 10.8. Bio-Rad Laboratories, Inc.

10.8.1. Company Overview

10.8.2. Key Executives

10.8.3. Company Snapshot

10.8.4. Operating Business Segments

10.8.5. Product Portfolio

10.8.6. Business Performance

10.8.7. Key Strategic Moves and Developments

## 10.9. Grifols, S.A.

10.9.1. Company Overview

10.9.2. Key Executives

10.9.3. Company Snapshot

10.9.4. Operating Business Segments

10.9.5. Product Portfolio

10.9.6. Business Performance

10.9.7. Key Strategic Moves and Developments

## 10.10. Exagen Inc.

10.10.1. Company Overview

10.10.2. Key Executives

10.10.3. Company Snapshot

10.10.4. Operating Business Segments

10.10.5. Product Portfolio

10.10.6. Business Performance

10.10.7. Key Strategic Moves and Developments



## I would like to order

Product name: Atorvastatin Calcium Market By Form (Tablets, Others) , By Application (Hypercholesterolemia, Hyperlipidemia, Others) By Distribution channel (Hospital pharmacies, Drug store & retail pharmacies, Online providers.) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Product link: <https://marketpublishers.com/r/ACB76400BC89EN.html>

Price: US\$ 2,655.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ACB76400BC89EN.html>